I read the following contribution from Milton Simba Kambarami: https://medium.com/microbial-instincts/pirola-covid-variant-has-evolved-again-showing-enhanced-immune-escape-3b37d94196d1. While warning about the ongoing immune escape, this person doesn't seem to realize that the spread of more infectious immune escape variants directly results from mass vaccination, which, since Omicron, has led to immune refocusing. Otherwise, they would not propose investing more money and resources into developing new Covid-19 (c-19) vaccines.
Which epitopes on spike protein that the circulating SARS-CoV-2 lineages have not yet developed resistance against should a new vaccine target? How can one even make a proposal about new vaccines without understanding the underlying dynamics of the evolving interactions between the host and the immune system? I strongly recommend this individual to subscribe to my course https://www.voiceforscienceandsolidarity.org/ to learn that:
Geert Vanden Bossche received his DVM from the University of Ghent, Belgium, and his PhD degree in Virology from the University of Hohenheim, Germany. He held adjunct faculty appointments at universities in Belgium and Germany. After his career in Academia, Geert joined several vaccine companies (GSK Biologicals, Novartis Vaccines, Solvay Biologicals) to serve various roles in vaccine R&D as well as in late vaccine development.
Geert then moved on to join the Bill & Melinda Gates Foundation’s Global Health Discovery team in Seattle (USA) as Senior Program Officer; he then worked with the Global Alliance for Vaccines and Immunization (GAVI) in Geneva as Senior Ebola Program Manager. At GAVI he tracked efforts to develop an Ebola vaccine. He also represented GAVI in fora with other partners, including WHO, to review progress on the fight against Ebola and to build plans for global pandemic preparedness.
Back in 2015, Geert scrutinized and questioned the safety of the Ebola vaccine that was used in ring vaccination trials conducted by WHO in Guinea. His critical scientific analysis and report on the data published by WHO in the Lancet in 2015 was sent to all international health and regulatory authorities involved in the Ebola vaccination program. After working for GAVI, Geert joined the German Center for Infection Research in Cologne as Head of the Vaccine Development Office. He is at present primarily serving as a Biotech / Vaccine consultant while also conducting his own research on Natural Killer cell-based vaccines.